EVZIO (AUTOINJECTOR)
Peaknaloxone hydrochloride
NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTIONPriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
0/100
Mechanism of Action
naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.
Loss of Exclusivity
LOE Date
Mar 20, 2035
110 months away
Patent Expiry
Mar 20, 2035